ULTRA PERFORMANCE LIQUID CHROMATOGRAPHIC METHOD DEVELOPMENT AND VALIDATION FOR THE DETERMINATION OF GLECAPREVIR AND PIBRENTASVIR IN PHARMACEUTICAL DOSAGE FORMS
2nd GLOBAL PHARMA SUMMIT
July 18-19, 2019 | Valencia, Spain
Vimta Labs Ltd., India
Scientific Tracks Abstracts : Asian J Biomed Pharmaceut Sci
The combination of Glecaprevir and Pibrentasvir is used to treat certain types of chronic hepatitis C infection. A new analytical method was developed and validated for the simultaneous determination of the Glecaprevir and Pibrentasvir in pharmaceutical dosage form by using UPLC. In this method, Chromatogram was run through HSSC18 (1.8μm 2.1x 100mm) column, mobile phase containing Potassium dihydrogen orthophosphate buffer (Adjusted using 30% v/v of ortho phosphoric acid pH 3.5) and Acetonitrie in the ratio of 30:70 was pumped through column at a flow rate of 0.3ml/min. Temperature was maintained at 30°C. Optimized wavelength for Glecaprevir and Pibrentasvir was 260nm. Retention times of Glecaprevir and Pibrentasvir were found to be 0.61min and 0.92min. The total run time was 2.0min. The percentage recovery was obtained as 98.4 and 99.2% for Glecaprevir and Pibrentasvir respectively. The developed method was validated as per ICH guidelines and hence it can be used for the routine analysis in various pharmaceutical industries and drug testing laboratories.
Poojitha Dhulipalla has completed her M Pharmacy from JSS University, Ooty, India. She is having two years of experience as auditor in the Quality Assurance Department in Pharmaceutical industry. She has over 10 publications in various reputed journals and attended various national and international conferences.
E-mail: [email protected]